A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
Adolescent
Adrenal Cortex Hormones
/ adverse effects
Adult
Adverse Drug Reaction Reporting Systems
Arthralgia
/ chemically induced
Ciprofloxacin
/ adverse effects
Connective Tissue Diseases
/ drug therapy
Databases, Factual
Drug-Related Side Effects and Adverse Reactions
Female
Fluoroquinolones
/ pharmacology
Humans
Levofloxacin
/ adverse effects
Male
Middle Aged
Moxifloxacin
/ adverse effects
Musculoskeletal Diseases
/ drug therapy
Myalgia
/ chemically induced
Norfloxacin
/ administration & dosage
Ofloxacin
/ administration & dosage
Pain
/ chemically induced
Risk Factors
Tendinopathy
/ chemically induced
Tendons
/ pathology
Young Adult
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
13 07 2021
13 07 2021
Historique:
received:
22
12
2020
accepted:
14
06
2021
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Recent drug safety concerns described fluoroquinolone (FQ)-induced serious musculoskeletal reactions. The objective of this study was to characterize reports with FQ-associated disabling musculoskeletal disorders, from VigiBase. The analysis included all FQ-induced musculoskeletal and connective tissue disorders adverse drug reaction (ADR) reports (up to July-2019), (disabling/incapacitating, or recovered/resolved with sequelae or fatal). We described aspects like reporter, suspected FQs, ADRs, associated corticosteroid therapy. We also looked into the disproportionality data in terms of proportional reporting ratio (PRR) and information component (IC) values. A total of 5355 reports with 13,563 ADRs and 5558 FQs were reported. The majority of reports were for patients aged 18-64 (62.67%), and the female gender prevailed (61.76%). Consumers reported almost half (45.99%), with a peak in reporting rates in 2017. Top reported ADRs were arthralgia (16.34%), tendonitis (11.04%), pain in extremity (9.98%), tendon pain (7.63%), and myalgia (7.17%). Top suspected FQs were levofloxacin (50.04%), ciprofloxacin (38.41%), moxifloxacin (5.16%), ofloxacin (3.17%) and norfloxacin (1.01%). For these, FQs-ADR association was supported by the disproportionality analysis. Corticosteroids were associated with about 7% of tendon related reports. The results augment the existing data on FQs safety concerns, specifically their potential effect on the musculoskeletal system.
Identifiants
pubmed: 34257376
doi: 10.1038/s41598-021-93763-y
pii: 10.1038/s41598-021-93763-y
pmc: PMC8277836
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Fluoroquinolones
0
Ciprofloxacin
5E8K9I0O4U
Levofloxacin
6GNT3Y5LMF
Ofloxacin
A4P49JAZ9H
Norfloxacin
N0F8P22L1P
Moxifloxacin
U188XYD42P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14375Informations de copyright
© 2021. The Author(s).
Références
Ther Clin Risk Manag. 2017 Sep 11;13:1195-1203
pubmed: 28979130
J Plast Reconstr Aesthet Surg. 2008 Jul;61(7):830-4
pubmed: 17409040
J Pharmacol Pharmacother. 2013 Dec;4(Suppl 1):S66-72
pubmed: 24347986
N Engl J Med. 1994 Sep 15;331(11):748
pubmed: 8058092
Drug Saf. 2013 Sep;36(9):709-21
pubmed: 23888427
Drug Saf. 2006;29(10):889-96
pubmed: 16970512
Int J Antimicrob Agents. 2009 Mar;33(3):194-200
pubmed: 18835137
Lancet Oncol. 2018 Dec;19(12):1579-1589
pubmed: 30442497
Drug Saf. 2008;31(6):515-24
pubmed: 18484785
Br J Clin Pharmacol. 2011 Dec;72(6):905-8
pubmed: 21658092
Clin Infect Dis. 2003 Jun 1;36(11):1404-10
pubmed: 12766835
Drugs Aging. 2010 Mar 1;27(3):193-209
pubmed: 20210367
Expert Opin Drug Saf. 2015;14(11):1653-60
pubmed: 26393387
Pharmacoecon Open. 2017 Jun;1(2):123-131
pubmed: 29442334
Curr Drug Saf. 2007 Jan;2(1):47-63
pubmed: 18690950
Eur J Clin Pharmacol. 2007 May;63(5):499-503
pubmed: 17334751
Int J Immunopathol Pharmacol. 2011 Apr-Jun;24(2):519-22
pubmed: 21658328
Eur J Clin Pharmacol. 2014 May;70(5):627-35
pubmed: 24599513
Drug Saf. 2010 Sep 1;33(9):789-99
pubmed: 20701411
Clin Pediatr (Phila). 2016 Feb;55(2):107-10
pubmed: 26260402
Urology. 2018 Mar;113:20-25
pubmed: 29074337
Pediatrics. 2016 Nov;138(5):
pubmed: 27940800
Pharmacoepidemiol Drug Saf. 2006 Nov;15(11):784-92
pubmed: 16456878
Emerg Med J. 2016 Jul;33(7):519-22
pubmed: 27330182
Drug Saf. 2018 Feb;41(2):203-212
pubmed: 28933055
Natl Med J India. 2017 Jul-Aug;30(4):203-207
pubmed: 29162753
Neuromuscul Disord. 2010 Jul;20(7):443-7
pubmed: 20621722
Am J Med. 2012 Dec;125(12):1228.e23-1228.e28
pubmed: 23026288
Am J Med. 1991 Dec 30;91(6A):35S-37S
pubmed: 1767805
Pharmacoepidemiol Drug Saf. 2012 Aug;21(8):886-9
pubmed: 22532516
Drug Saf. 2020 Jan;43(1):7-16
pubmed: 31617080
Drugs Real World Outcomes. 2018 Jun;5(2):117-128
pubmed: 29725886
Drugs. 2002;62(1):13-59
pubmed: 11790155
J Pharm Policy Pract. 2019 Apr 9;12:8
pubmed: 31007933
PLoS One. 2013 Sep 04;8(9):e73166
pubmed: 24023828
Br J Clin Pharmacol. 1999 Sep;48(3):433-7
pubmed: 10510157